GlassScriptPhysician profile
Deepak Angara Rao
NPI 1770803629
$64,158.52
in general payments reported to CMS, 2019-2025
9 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $3,679 · 2022: $13K · 2023: $6,088 · 2024: $6,006 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,815 · Food and Beverage: $234 · Travel and Lodging: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,972.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,815.00 |
| Food and Beverage | $233.71 |
| Travel and Lodging | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $13,774.79 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $9,056.36 | 2019-2025 | |
| Janssen Research & Development, LLC | $7,851.29 | 2019-2020 | |
| Biogen, INC. | $6,866.69 | 2025 | |
| Astrazeneca Uk Limited | $6,444.00 | 2023-2025 | |
| Pfizer INC. | $6,000.00 | 2019-2022 | |
| Glaxosmithkline, LLC. | $5,743.39 | 2019-2023 | |
| Abbvie INC. | $5,200.00 | 2024 | |
| Astrazeneca Ab | $3,222.00 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.